linjc16/ctgov huggingface dataset:
The Effect of Medical Exercise Therapy on Pain, Function and Physical Activity in Patients With Knee Osteoarthritis

Study Overview
=================
Brief Summary
-----------------
The aim of the project is to investigate effects of medical exercise therapy (MET) on patients with knee osteoarthritis. MET is a common physical therapy intervention, and the project aim to strengthen the evidence of this intervention. An experimental cohort design is chosen, and 20 participants will be followed for 6 months. Assessments will be clinical tests, questionnaires and accelerometer measurements before, during, and after a 3 month period of exercise (3 days per week) with a physical therapist. The project will answer if a 3 month physical therapy intervention using MET causes changes in pain level, function and activity level for patients with knee osteoarthritis. In addition, it will investigate whether a single global endurance workout for 30 minutes will have an effect on pain level for these patients

Official Title
-----------------
The Effect of Medical Exercise Therapy on Pain, Function and Physical Activity in Patients With Knee Osteoarthritis

Conditions
-----------------
Osteoarthritis, Knee

Intervention / Treatment
-----------------
* Behavioral: Medical Exercise Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: x-ray verified knee osteoarthritis (Kellegren & Lawrence grade I-III) Loss of function and withstanding pain >3 months Exclusion Criteria: physical therapy treatment during the last 3 months knee injury inflammatory arthritis symptoms from the hip joints greater than the knee pain planned knee surgery the next 6 months heart and lung disorders or other health issues affecting the ability to complete the intervention

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Medical Exercise Therapy<br>Medical Exercise Therapy (MET) developed by Oddvar Holten | Behavioral: Medical Exercise Therapy<br>* physiotherapy intervention with Medical exercise therapy (MET) during 3 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain | visual analog scale | 6 months | 
| Activity level | Accelerometer | 6 months | 
| Function | 30 second chair stand test | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Exercise Therapy, Musculoskeletal Pain, Knee osteoarthritis, Physical Therapy Modalities
REALM China Extension Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to conduct an investigator initiated observational study to continue to follow up the China subset of study participants for another 5 years after they complete participation in the REALM Study

Official Title
-----------------
A 5-Year Follow-up Study of Subjects Who Completed REALM-China Study

Conditions
-----------------
Hepatitis B, Chronic

Intervention / Treatment
-----------------
* Other: follow-up


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients completed REALM Study in China Patients willing to sign the consent to continue anti-viral treatment or post-treatment follow up, and agree his/her legacy data and blood/liver histology samples collected in REALM Study may be used for the analyses planned for this new study. Exclusion Criteria: Patients who do not provide consent to participate in this study; Patients are formally enrolled into any investigational drug clinical trial after the REALM study.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All patients<br>Continuing with marketed anti-HBV or off-treatment in real-life setting | Other: follow-up<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment patterns in Study AI463520 |  | year 5 | 
| Incidence rates of hepatitis B virus (HBV)-related clinical outcome events (COEs), such as non-hepatocellular carcinoma (HCC) HBV progression, HCC, and liver-related mortality, in Studies AI463080 and AI463520 combined, and in Study AI463520. |  | year 5 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antiviral efficacy endpoints on anti-HBV treatment in Studies AI463080 and AI463520. |  | year 5 | 
| Multivariate logistic regression models evaluating the relationship between pre-treatment biomarkers and antiviral efficacy endpoints on anti-HBV treatment in Study |  | year 5 | 
| Multivariate logistic regression models evaluating the relationship between baseline liver stiffness measurement (LSM) and HBV-related COEs outcomes in Study AI463520. |  | year 5 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Hepatitis B
Platelets Indices and Its Role to Predict Liver Fibrosis in Patients With Chronic Hepatitis B Infection

Study Overview
=================
Brief Summary
-----------------
Platelets indices and its role to predict liver Fibrosis in patients with chronic hepatitis B infection

Detailed Description
-----------------
Patients with chronic Hepatitis B infection will be collected and will do liver fibroscan to predict the degree of liver Fibrosis and correlate between the role of platelets count and degree of liver Fibrosis in patients with Chronic hepatitis B virus

Official Title
-----------------
Platelets Indices and Its Role to Predict Liver Fibrosis in Patients With Chronic Hepatitis B Infection

Conditions
-----------------
Fibrosis, Liver

Intervention / Treatment
-----------------
* Radiation: Liver Fibroscan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age from 18 to 70 years without a history of clinical illness Exclusion Criteria: with other hepatitis virus infection; (b) with alcoholic liver disease; (c) with any disease related to fibrosis (such as connective tissue diseases, chronic obstructive pulmonary disease, kidney failure, tumors, and so on); (d) have received any anti-fibrosis therapy; and (e) pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 75<br>patients with chronic hepatitis B infection will be collected and underwill liver fibroscan then corelate between platelets indicies and predict degree of liver fibrosis | Radiation: Liver Fibroscan<br>* Patients with CHB virus will do liver fibroscan and correlat between platelets count and degree of liver fibrosis<br>* Other names: Elastography and Fibroscan;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Platelets indices and its role to predict liver Fibrosis in patients with chronic hepatitis B infection | Correlation between platelets count and degree of liver Fibrosis in patients with chronic hepatitis B virus through liver fibroscan | Two years |
GSK BHR Study (Sont)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to determine whether asthma control and reduced bronchial hyperresponsiveness could be achieved and maintained at a lower dose of inhaled corticosteroids with ADVAIR DISKUS twice-daily or FP twice-daily in adult and adolescent subjects with persistent asthma

Official Title
-----------------
A Multicenter, Randomized, Double-blind, Parallel Group, 40-week Comparison of Asthma Control Using Bronchial Hyperresponsiveness as an Additional Guide to Long-term Treatment in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUS Twice Daily or Fluticasone Propionate DISKUS Twice Daily (or Placebo BID if Asymptomatic)

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: Placebo
* Drug: FP 100mcg
* Drug: FP 500mcg
* Drug: FP 250mcg
* Drug: FSC 100/50mcg
* Drug: FSC 250/50mcg
* Drug: FSC 500/50mcg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Asthma diagnosis Controller medications or moderate inhaled corticosteroid dose Evidence of reversibility Exclusion Criteria: Life-threatening asthma Asthma instability Concurrent respiratory disease Drug allergy Respiratory tract infection Systemic corticosteroid use Immunosuppressive medication use Positive pregnancy test Tobacco use Site affiliation

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Fluticasone propionate<br> | Drug: Placebo<br>* Twice daily dosing<br>Drug: FP 100mcg<br>* Twice daily dosing<br>Drug: FP 500mcg<br>* Twice daily dosing<br>Drug: FP 250mcg<br>* Twice daily dosing<br>|
| Active Comparator: Fluticasone propionate/salmeterol combination<br> | Drug: Placebo<br>* Twice daily dosing<br>Drug: FSC 100/50mcg<br>* Twice daily dosing<br>Drug: FSC 250/50mcg<br>* Twice daily dosing<br>Drug: FSC 500/50mcg<br>* Twice daily dosing<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Average inhaled corticosteroid treatment dose over the treatment period |  | Every 8 weeks for the 40 week treatment period | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pulmonary function measures |  | Every 8 weeks for the 40 week treatment period |
Preoperative Breast Magnetic Resonance Imaging for Patients Undergoing Mammoplasty

Study Overview
=================
Brief Summary
-----------------
all female with operable breast cancer seeking health care at general surgery department Assiut university hospitals,and decision of therapeutic mammoplasty was taken depending on clinical examination, findings on mammography and sonography, will undergo MRI breast, and see if MRI finding will change decision of the surgery.

Detailed Description
-----------------
Study Setting: Assiut university hospital, general surgery department (C unit ) Study subjects: all female with operable breast cancer seeking health care at general surgery department and decision of therapeutic mammoplasty was taken depending on clinical examination, findings on mammography and sonography. The size, number, and location of breast cancer lesions were identified on US and mammography. Also size, number, location, pattern of enhancement and presence or absence of intraductal component will be evaluated by preoperative MRI. The surgical plane will be decided based on US and mammography findings. The final decision will be based on MRI findings. When the initial surgical decision was the same as final decision the patient will be assigned to the unchanged group. However, if the final decision differed from the initial surgical decision the patient will be assigned to the changed group.

Official Title
-----------------
The Role of Preoperative Breast Magnetic Resonance Imaging for Surgical Decision in Patients Undergoing Therapeutic Mammoplasty

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Other: magnetic resonance imaging of breast


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female patient with operable breast cancer (stage 1 and 2 ) Patient meet the criteria of therapeutic mammoplasty Exclusion Criteria: Inoperable breast cancer (stage 3 and 4) Breast cancer size > 4 cm in diameter Previous radiotherapy Local recurrence after previous breast conservation surgery Male breast cancer
Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: magnetic resonance imaging of breast|all patients will undergo preoperative MRI|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of patients whom MRI finding that will change the decision of surgery |  | 1 year |
Collection of Bone Marrow Aspirate From Volunteer Donors

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to collect bone marrow cells for research purposes.

Detailed Description
-----------------
This study is designed to provide bone marrow cells for other research studies. The research is being done because there are ongoing experiments in a number of National Institute on Aging (NIA) laboratories that require access to normal human bone marrow aspirate for their studies of the immune system. These studies are done to understand how blood cells are formed and how they function. Samples will be used to study problems such as the immune system in bone marrow failure and related conditions. Cells will be used in laboratory research and may be banked for future laboratory studies

Official Title
-----------------
Collection of Bone Marrow Aspirate From Volunteer Donors for In Vitro Hematopoietic Research

Conditions
-----------------
Aging

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy volunteers age 18 and over Exclusion Criteria: Significant abnormalities on health history questionnaire or in the results of blood tests Pregnant or nursing mother Participation in another research study within the past six weeks that is felt by the Principal Investigator to be incompatible with this study Severe infection in the past two months Immune disorder, or use of any medication that can alter immune system function A medical or mental health finding showing inability to go through the procedure Body mass index (BMI) greater than 29% Chronic back pain, sciatica, or a compression fracture of the spine Positive test results for viral infections: Hepatitis B, Hepatitis C, or HIV (AIDS)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Trial of Immediate vs. Delayed Cord Clamping in the Preterm Neonate

Study Overview
=================
Brief Summary
-----------------
To determine the short and long term effects of placental transfusion at birth by milking and delayed cord clamping of the umbilical cord in neonates born between 24 weeks 0 days and 34 weeks 0 days weeks' gestation.

Detailed Description
-----------------
This study is intended to be a randomized controlled trial comparing immediate cord clamping which represents the current standard of care at Oklahoma University Medical Center with delayed cord clamping among preterm neonates born between 24 weeks and 34 weeks 0 days weeks' gestation. Allocation sequence will be generated by simple randomization using random number table in the stratum 24-28 weeks 6 days and 29 weeks to 34 weeks 0 days weeks' gestation stratum.

Official Title
-----------------
A Randomized Controlled Trial of Immediate Versus Delayed Cord Clamping in the Preterm Neonate

Conditions
-----------------
PreTerm Birth, PreTerm Neonate

Intervention / Treatment
-----------------
* Procedure: Delayed Cord Clamping
* Procedure: Immediate Cord Clamping


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Singleton pregnancies Signed consent to participate in the trial Exclusion Criteria: Major fetal anomaly or known fetal chromosomal abnormalities Multiple gestation Mothers with pregestational and gestational diabetes Refusal to participate in the trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>Delayed Cord Clamping | Procedure: Delayed Cord Clamping<br>* Delayed Cord Clamping: 30-35 seconds after birth<br>|
| Active Comparator: B<br>Immediate cord clamping | Procedure: Immediate Cord Clamping<br>* Immediate Cord Clamping: within 5 seconds of birth<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the short and long term effects of placental transfusion at birth by milking and delayed cord clamping of the umbilical cord in neonates born between 24 weeks 0 days and 34 weeks 0 days weeks' gestation. |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PreTerm Birth, PreTerm Neonate, High risk pregnancy, Preterm Baby, Premature Baby, Cord Clamping, Milking the cord
Vestibular Dysfunction as a Cause of Chronic Nausea & Vomiting: A Follow up Survey

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to characterize the accompanying symptoms, evaluation and management of patients with chronic vestibular dysfunction presenting with nausea and vomiting.

Detailed Description
-----------------
Based on prior study, a significant portion of patients referred for refractory gastroparesis in fact have signs suggestive of vestibular dysfunction as the cause of chronic nausea and vomiting. Our prior retrospective study identified a population of said subjects. The aim of this study is to further characterize the concomitant symptoms, course of diagnosis, treatment and long-term follow up (up to 5 yrs) of this condition.

Official Title
-----------------
Vestibular Dysfunction as a Cause of Chronic Nausea & Vomiting: A Follow up Study

Conditions
-----------------
Dysfunction of Vestibular System, Nausea Persistent, Vomiting

Intervention / Treatment
-----------------
* Other: Questionnaire survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical symptoms of nausea and vomiting for at least 4 weeks Abnormal modified Fukuda stepping test on examination (>90 degree rotation from midline while marching in place for 60 seconds) or nystagmus or abnormal Rhomberg test Exclusion Criteria: Pregnancy Unable to complete questionnaire survey

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Questionnaire survey|Mailed questionnaire investigating response to empiric treatment trials, further investigations by otolarygology and possible alternative diagnoses.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement of nausea and vomiting |  | 1 to 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Associated symptoms |  | 1 to 2 months | 
| Alternate diagnoses |  | 1 to 2 months |
Muscle Evaluation Using Ultrasound in the Critically Ill

Study Overview
=================
Brief Summary
-----------------
Critical illness is associated with ICU acquired weakness and diaphragmatic dysfunction. Ultrasound can evaluate the muscle mass non invasively and provides the ability for a muscle follow up during and after the ICU stay. Magnetic stimulation of the phrenic nerves and the measure of the end expiratory tracheal pressure with an occlusion valve allows to evaluate the diaphragm force production in mechanically ventilated patients. The aim of the present study is to constitute an image bank and to describe the muscle mass and function recovery in critically ill patients.

Detailed Description
-----------------
Critical illness is associated with ICU acquired weakness and diaphragmatic dysfunction. Ultrasound can evaluate the muscle mass non invasively and provides the ability for a muscle follow up during and after the ICU stay. Magnetic stimulation of the phrenic nerves and the measure of the end expiratory tracheal pressure with an occlusion valve allows to evaluate the diaphragm force production in mechanically ventilated patients. The aim of the present study is to constitute an image bank and to describe the mass and function recovery in critically ill patients. Ultrasound and clinical data will be collected and analysed during the ICU stay.

Official Title
-----------------
Muscle Evaluation Using Ultrasound in the Critically Ill : ULTRAMUSCLE Study

Conditions
-----------------
Critical Illness, ICU Acquired Weakness

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Critically ill patients with at least one organ failure defined, organ failure being defined by a SOFA equal or above 3 for the organ, and an expected duration of ICU stay equal of above 3 days Exclusion criteria: - Pregnancy, age below 18, absence of consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ultrasound characteristics of the quadriceps | Changes in ultrasound characteristics of the quadriceps : cross sectional area of quadriceps (cm2) | Since admission at day 0 and measured repetitively by 48 hours untildischarge from ICU or date of death from any cause, whichever came first, assessed up to day 28 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diaphragmatic dysfunction, Mechanical Ventilation, ICU acquired weakness, Weaning, Skeletal muscles, Respiratory muscles